News

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

This episode covers Abbott’s Libre Duo and Libre Duo 10 Day systems, Eli Lilly’s retatrutide, and the recent Dexcom sensor theft.

Saroglitazar received FDA Priority Review for adults with PBC after phase 3 data showed improved biochemical response versus placebo.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

This segment of the latest Skin of Color Savvy podcast highlighted persistent disparities in skin cancer prevention, awareness, and diagnosis.

At ATS 2026, Sarath Raju, MD, discussed retrospective data linking SGLT2 inhibitor use to reduced 30-day readmissions in patients hospitalized for AE-COPD and diabetes.

Ferdinand shares his advice on high blood pressure management, drawing on his perspective as co-author of the ACC/AHA 2025 hypertension guidelines.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

The approval indicates linaclotide for pediatric patients ≥ 2 years of age with functional constipation, expanding its previous use in patients ≥ 6 years of age.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.

FDA De Novo classification clears Cardiosense PCWP Analysis Software to estimate filling pressures in selected adults with HFrEF.

The Liver Disease Panel represents the first comprehensive library of certified healthcare algorithms to support chronic liver disease management.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.

A quantitative CT-based approach may help predict pneumothorax risk after bronchoscopic lung volume reduction, according to findings presented at ATS 2026.

Jason Guichard, MD, PhD, lead author of the study, discusses positive 2-year data from the investigative trial of the Cordella Pulmonary Artery Sensor System.

ATS 2026 data presented by Jamey Moore, DO, suggest greater upfront corticosteroid dosing may shorten hospitalization in acute exacerbations of autoimmune-related ILD.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.

This episode highlights the importance of closing persistent gaps in skin cancer prevention and awareness for patients with skin of color.

Goodyear explores how the medical community often downplays this risk and why it's time for a more transparent, patient-first conversation.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

This Q&A interview highlights the broader implications of the phase 3b TOGETHER-PsO trial for ixekizumab and tirzepatide in managing psoriatic disease.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.

Miedema highlights the shortcomings of current technology and medication for what is among the US’s fastest-growing and most devastating conditions.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

Until this decision, clinicians relied on off-label, interferon-based regimens with limited efficacy.